Sodium-Glucose Cotransporter-2 Inhibitors in Diabetic Patients with Heart Failure: An Update
Diabetes mellitus and heart failure are two diseases that are commonly found together, in particular in older patients. High blood glucose has a detrimental effect on the cardiovascular system, and worse glycemic control contributes to the onset and the recrudesce of heart failure. Therefore, any sp...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-10-01
|
| Series: | Pharmaceuticals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1424-8247/17/11/1419 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850226301141516288 |
|---|---|
| author | Nicia I. Profili Roberto Castelli Antonio Gidaro Roberto Manetti Margherita Maioli Alessandro P. Delitala |
| author_facet | Nicia I. Profili Roberto Castelli Antonio Gidaro Roberto Manetti Margherita Maioli Alessandro P. Delitala |
| author_sort | Nicia I. Profili |
| collection | DOAJ |
| description | Diabetes mellitus and heart failure are two diseases that are commonly found together, in particular in older patients. High blood glucose has a detrimental effect on the cardiovascular system, and worse glycemic control contributes to the onset and the recrudesce of heart failure. Therefore, any specific treatment aimed to reduce glycated hemoglobin may, in turn, have a beneficial effect on heart failure. Sodium-glucose cotransporter-2 inhibitors have been initially developed for the treatment of type 2 diabetes mellitus, and their significant action is to increase glycosuria, which in turn causes a reduction in glucose blood level and contributes to the reduction of cardiovascular risk. However, recent clinical trials have progressively demonstrated that the glycosuric effect of the sodium-glucose cotransporter-2 inhibitors also have a diuretic effect, which is a crucial target in the management of patients with heart failure. Additional studies also documented that sodium-glucose cotransporter-2 inhibitors improve the therapeutical management of heart failure, independently by the glycemic control and, therefore, by the presence of diabetes mellitus. In this review, we analyzed studies and trials demonstrating the efficacy of sodium-glucose cotransporter-2 inhibitors in treating chronic and acute heart failure. |
| format | Article |
| id | doaj-art-5a5b4d98c205475eac1329be22ece3af |
| institution | OA Journals |
| issn | 1424-8247 |
| language | English |
| publishDate | 2024-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceuticals |
| spelling | doaj-art-5a5b4d98c205475eac1329be22ece3af2025-08-20T02:05:07ZengMDPI AGPharmaceuticals1424-82472024-10-011711141910.3390/ph17111419Sodium-Glucose Cotransporter-2 Inhibitors in Diabetic Patients with Heart Failure: An UpdateNicia I. Profili0Roberto Castelli1Antonio Gidaro2Roberto Manetti3Margherita Maioli4Alessandro P. Delitala5Department of Medicine, Surgery and Pharmacy, University of Sassari, 07100 Sassari, ItalyDepartment of Medicine, Surgery and Pharmacy, University of Sassari, 07100 Sassari, ItalyDepartment of Biomedical and Clinical Sciences Luigi Sacco, Luigi Sacco Hospital, University of Milan, 20157 Milan, ItalyDepartment of Medicine, Surgery and Pharmacy, University of Sassari, 07100 Sassari, ItalyDepartment of Biochemical Science, University of Sassari, 07100 Sassari, ItalyDepartment of Medicine, Surgery and Pharmacy, University of Sassari, 07100 Sassari, ItalyDiabetes mellitus and heart failure are two diseases that are commonly found together, in particular in older patients. High blood glucose has a detrimental effect on the cardiovascular system, and worse glycemic control contributes to the onset and the recrudesce of heart failure. Therefore, any specific treatment aimed to reduce glycated hemoglobin may, in turn, have a beneficial effect on heart failure. Sodium-glucose cotransporter-2 inhibitors have been initially developed for the treatment of type 2 diabetes mellitus, and their significant action is to increase glycosuria, which in turn causes a reduction in glucose blood level and contributes to the reduction of cardiovascular risk. However, recent clinical trials have progressively demonstrated that the glycosuric effect of the sodium-glucose cotransporter-2 inhibitors also have a diuretic effect, which is a crucial target in the management of patients with heart failure. Additional studies also documented that sodium-glucose cotransporter-2 inhibitors improve the therapeutical management of heart failure, independently by the glycemic control and, therefore, by the presence of diabetes mellitus. In this review, we analyzed studies and trials demonstrating the efficacy of sodium-glucose cotransporter-2 inhibitors in treating chronic and acute heart failure.https://www.mdpi.com/1424-8247/17/11/1419SGLT2iNa<sup>+</sup>-glucose cotransporter-2 inhibitorschronic heart failureacute heart failurediabetescardiovascular disease |
| spellingShingle | Nicia I. Profili Roberto Castelli Antonio Gidaro Roberto Manetti Margherita Maioli Alessandro P. Delitala Sodium-Glucose Cotransporter-2 Inhibitors in Diabetic Patients with Heart Failure: An Update Pharmaceuticals SGLT2i Na<sup>+</sup>-glucose cotransporter-2 inhibitors chronic heart failure acute heart failure diabetes cardiovascular disease |
| title | Sodium-Glucose Cotransporter-2 Inhibitors in Diabetic Patients with Heart Failure: An Update |
| title_full | Sodium-Glucose Cotransporter-2 Inhibitors in Diabetic Patients with Heart Failure: An Update |
| title_fullStr | Sodium-Glucose Cotransporter-2 Inhibitors in Diabetic Patients with Heart Failure: An Update |
| title_full_unstemmed | Sodium-Glucose Cotransporter-2 Inhibitors in Diabetic Patients with Heart Failure: An Update |
| title_short | Sodium-Glucose Cotransporter-2 Inhibitors in Diabetic Patients with Heart Failure: An Update |
| title_sort | sodium glucose cotransporter 2 inhibitors in diabetic patients with heart failure an update |
| topic | SGLT2i Na<sup>+</sup>-glucose cotransporter-2 inhibitors chronic heart failure acute heart failure diabetes cardiovascular disease |
| url | https://www.mdpi.com/1424-8247/17/11/1419 |
| work_keys_str_mv | AT niciaiprofili sodiumglucosecotransporter2inhibitorsindiabeticpatientswithheartfailureanupdate AT robertocastelli sodiumglucosecotransporter2inhibitorsindiabeticpatientswithheartfailureanupdate AT antoniogidaro sodiumglucosecotransporter2inhibitorsindiabeticpatientswithheartfailureanupdate AT robertomanetti sodiumglucosecotransporter2inhibitorsindiabeticpatientswithheartfailureanupdate AT margheritamaioli sodiumglucosecotransporter2inhibitorsindiabeticpatientswithheartfailureanupdate AT alessandropdelitala sodiumglucosecotransporter2inhibitorsindiabeticpatientswithheartfailureanupdate |